Article>Use of Psychotropic Medications in the HIV-Positive Patient Part IVergara-Rodriguez, Pamela MD; Watts, Jeff MDEditor(s): Janicak, Philip G. MD Author Information Dr. Vergara-Rodriguez is Internist/Psychiatrist, and Dr. Watts is Clinic Psychiatric Coordinator, Ruth M. Rothstein CORE Center, 2020 W. Harrison Street, Chicago, IL 60612; E-mail: [email protected]. Dr. Vergara-Rodriguez has disclosed that she has no significant relationships with or financial interests in any commercial organizations pertaining to this educational activity. Dr. Watts has disclosed that he is/was a member of the speakers bureaus of Abbott Virology and BMS Virology. The authors also have disclosed that trazodone for insomnia, stimulants for symptoms of depression, venlafaxine XR and gabapentin for neuropathic pain, and citalopram for anxiety disorders as discussed in this article have not been approved by the U.S. Food and Drug Administration All faculty and staff in a position to control the content of this CME activity have disclosed that they have no financial relationships with, or financial interests in, any commercial companies pertaining to this educational activity. Lippincott CME Institute, Inc., has identified and resolved all faculty and staff conflicts of interest regarding this educational activity. This article is the first of two parts. Psychopharm Review: August 2008 - Volume 43 - Issue 8 - p 59-65 doi: 10.1097/01.IDT.0000330316.55872.6b Buy CME Test Metrics © 2008 Lippincott Williams & Wilkins, Inc.